Trial Profile
Pilot Trial of Anastrozole and Palbociclib as First-Line Therapy and as Maintenance Therapy After First Line Chemotherapy in Hormone Receptor Positive, HER2-Negative Postmenopausal Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 23 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2022 Planned End Date changed from 1 Oct 2022 to 30 Jun 2026.
- 21 Feb 2022 Planned primary completion date changed from 31 Jan 2022 to 30 Jun 2026.